Cancer and Metastasis Reviews

, Volume 32, Issue 1, pp 109–122

Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic

Authors

  • Shazia Irshad
    • Herbert Irving Comprehensive Cancer Center, Departments of Urology and Pathology & Cell BiologyColumbia University College of Physicians and Surgeons
    • Herbert Irving Comprehensive Cancer Center, Departments of Urology and Pathology & Cell BiologyColumbia University College of Physicians and Surgeons
    • Herbert Irving Comprehensive Cancer CenterColumbia University College of Physicians and Surgeons
Article

DOI: 10.1007/s10555-012-9409-1

Cite this article as:
Irshad, S. & Abate-Shen, C. Cancer Metastasis Rev (2013) 32: 109. doi:10.1007/s10555-012-9409-1

Abstract

More than 15 years ago, the first generation of genetically engineered mouse (GEM) models of prostate cancer was introduced. These transgenic models utilized prostate-specific promoters to express SV40 oncogenes specifically in prostate epithelium. Since the description of these initial models, there have been a plethora of GEM models of prostate cancer representing various perturbations of oncogenes or tumor suppressors, either alone or in combination. This review describes these GEM models, focusing on their relevance for human prostate cancer and highlighting their strengths and limitations, as well as opportunities for the future.

Keywords

Prostate cancerGenetically engineered miceGEM models

Copyright information

© Springer Science+Business Media New York 2012